Novo Nordisk reported 42.77B in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Bausch Health Companies USD 2.07B 90M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
Merck USD 9.44B 217M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Novo Nordisk 42.77B 3.48B Jun/2025
Novo Nordisk DKK 39.3B 1.81B Mar/2025
Pacira USD 170.87M 3.93M Jun/2025
Sanofi EUR 9.02B 702M Jun/2025
Supernus Pharmaceuticals USD 153.31M 892K Jun/2025